Metformin for Pulmonary Hypertension HFpEF
NCT03629340
Cardiovascular Diseases, Heart Diseases
San Francisco, California, United States
View Trial DetailsNCT Number: NCT02743091
This study investigates the prevalence and prognosis of idiopathic pre-capillary pulmonary hypertension (PH) in patients with end-stage kidney disease (ESKD).
Looking for future studies?
Notify Me50 year–85 year
All sexes
Observational
Pulmonary hypertension (PH) is a rare cardiovascular disease with progressive and fatal features. PH is classified into the 5 groups, and the prevalence of group 1 pulmonary arterial hypertension, including idiopathic and heritable, is 5 to 15 cases per one million adults and a median survival was reportedly three years. PH found in patients with end-stage kidney disease (ESKD) is classified into group 5, because the pathogenesis and clinical characteristics have not been clarified. The prevalence of PH in patients with ESKD was reportedly around 17~56% based on echocardiographic studies. In this study, we evaluated the incidence of idiopathic pre-capillary PH of ESKD patients by right heart catheterization, and examined the prognosis by following the occurrence of heart failure death.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 14 years
Time frame: 14 years
Toujinkai Hospital
Other
Idiopathic Pre-capillary Pulmonary Hypertension in Patients With End-stage Kidney Disease
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03629340
Cardiovascular Diseases, Heart Diseases
San Francisco, California, United States
View Trial DetailsNCT06671171
Arterial Occlusive Diseases, Arteriosclerosis
Hong Kong
View Trial DetailsNCT07512310
Cardiovascular Diseases, Heart Diseases
Essen, Germany
View Trial DetailsNCT05996562
Cardiovascular Diseases, Heart Diseases
Lisbon, Portugal
View Trial Details